Targeted and effective glioblastoma therapy via aptamer-modified tetrahedral framework nucleic acid-paclitaxel nanoconjugates that can pass the blood brain barrier

• Published in: Nanomedicine 2019-10, Vol.21, p.102061-102061, Article 102061
• Main Authors: Shi, Sirong, Fu, Wei, Lin, Shiyu, Tian, Taoran, Li, Songhang, Shao, Xiaoru, Zhang, Yuxin, Zhang, Tao, Tang, Zisheng, Zhou, Yi, Lin, Yunfeng, Cai, Xiaoxiao
• Format: Article
• Language: English
• Subjects: Gint4.T-tFNA-GMT8; Gint4.T-tFNA-GMT8/paclitaxel complexes; Glioblastoma multiforme; Tetrahedral framework nucleic acid
• ISSN: 1549-9634; 1549-9642
• DOI: 10.1016/j.nano.2019.102061

Targeted DNA nanoparticles have been identified as one of the most promising nanocarriers in anti-glioma drug delivery. We established a multifunctional nanosystem for targeted glioma therapy. Tetrahedral framework nucleic acid (tFNA), entering U87MG cells and bEnd.3 cells, was chosen to deliver two aptamers, GMT8 and Gint4.T, and paclitaxel. GMT8 and Gint4.T, which specifically bind with U87MG cells and with PDGFRβ, were linked with tFNA, to form Gint4.T-tFNA-GMT8 (GTG). GTG was efficiently internalized by U87MG and bEnd.3 cells and penetrated an in-vitro blood–brain-barrier model. GTG loaded with paclitaxel (GPC) had potentiated anti-glioma efficacy. It inhibited the proliferation, migration, and invasion of U87MG cells, and enhanced apoptosis induction in these cells. The expression of apoptosis-related proteins was significantly changed after treatment with GPC, confirming apoptosis induction. Our study demonstrated that the combination of GTG and paclitaxel has great potential for glioma treatment and tFNA shows great promise for use in drug delivery. The graphical abstract shows the preparation of GPC and the mechanism of GPC inducing apoptosis of U87MG cells via crossing the blood–brain barrier and targeting U87MG cells. [Display omitted]